PPACA: What’s Next For Life Sciences Companies


Law360, New York (August 24, 2012, 12:57 PM ET) -- Life sciences companies breathed a sigh of relief when the U.S. Supreme Court largely upheld the Patient Protection and Affordable Care Act (PPACA). After all, the PPACA will add millions of Americans to the pool of health care consumers. But the Supreme Court also held that the federally subsidized Medicaid expansion is optional for the states; therefore, as recently confirmed by the U.S. Congressional Budget Office, fewer people will be added to the pool than originally projected. As a result, drug manufacturers might not receive the full benefit of the bargain they made with Congress — an estimated $80-110 billion in rebates and discounts, which was based on the assumption that 17 million new customers would be eligible for Medicaid under the PPACA. Some will gain and some will lose under the PPACA decision. What’s for sure is that there will be changes for life sciences companies. The pharmaceutical industry, in particular, is in the midst of patent expirations on major blockbuster drugs, resulting in a staggering loss of revenues estimated at $127 billion over the next 5 years. However, no life sciences company is immune to the increasing pricing pressure, rising regulatory approval hurdles and the ever-expanding maze of health care providers, payors and regulators. We highlight below the key provisions of the PPACA and how they affect pharmaceutical, biotech and medical device companies after the Supreme Court’s decision.

- The PPACA and Biosimilars

- The Medical Device Tax

- Sunshine Reporting

- Tech Assessment and Diffusion under PCORI and IPAB

- Customers and Patients


Life sciences companies have always had to pay attention to state and regional differences in commercializing their products. However, with the anticipated variations in Medicaid expansion and health exchange adoption, manufacturers must pay even greater attention to states as they contemplate the PPACA’s impact on their customer base. Further, cost control efforts and ACOs are on the horizon. Life sciences companies can thrive under the PPACA, provided they account for areas of uncertainty and focus on proving the value of their products to purchasers and patients.

--By Konstantin Linnik, Ph.D., and Maria Buckley, Nutter McClennen & Fish LLP, and Andrew McArdell, Harvard Law School. (Konstantin Linnik is a partner and Maria Buckley is of counsel in Nutter McClennen's Boston office. Andrew McArdell is a student at Harvard Law School.)

Re-published with permission of Portfolio Media, Inc.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Konstantin Linnik, JD, PhD, Nutter McClennen & Fish LLP | Attorney Advertising

Written by:


Nutter McClennen & Fish LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.